Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

Roche Acquires Verum Diagnostica GmbH as Part of

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
SAE Member Profile
 
Followed By 2
Posts 564
Boards Moderated 0
Alias Born 08/06/09
160x600 placeholder
FDA panel votes to keep indications for Merck, Roche bladder cancer drugs Seeking Alpha - 4/30/2021 7:58:15 AM
FDA panel votes to maintain breast cancer indication for Roche's Tecentriq Seeking Alpha - 4/27/2021 5:26:34 PM
Roche Gets FDA Approval for Cancer-Treatment Test Dow Jones News - 4/23/2021 6:47:00 AM
Roche Q1 sales beats forecast, 2021 outlook confirmed Seeking Alpha - 4/21/2021 5:35:48 AM
Roche Holding beats on revenue; 2021 outlook confirmed Seeking Alpha - 4/21/2021 4:43:18 AM
Roche Backs 2021 Views After 1Q Sales Fall Slightly Dow Jones News - 4/21/2021 1:54:00 AM
Novartis to help produce Roche's Actemra Seeking Alpha - 4/15/2021 5:38:12 AM
Roche’s Evrysdi continues to improve motor function, survival in babies with spinal muscular atrophy Seeking Alpha - 4/15/2021 3:11:36 AM
Novartis Enters Agreement With Roche on Production of the Latter's Drug Dow Jones News - 4/15/2021 2:14:00 AM
Roche's Spark in Gene-Therapy Collaboration With Senti Bio Dow Jones News - 4/13/2021 10:10:00 AM
Roche unit Spark Therapeutics inks deal to bolster gene therapy research platform Seeking Alpha - 4/13/2021 9:16:17 AM
Novartis, Genentech Get FDA OK of Self-Administered Xolair Dow Jones News - 4/12/2021 2:12:00 PM
Roche's Phase 3 Trial of Casirivimab, Imdevimab Shows Cut Risk of Symptomatic Covid-19 Infections Dow Jones News - 4/12/2021 1:52:00 AM
Roche's Elecsys COVID-19 antibody test now available in Canada Seeking Alpha - 4/6/2021 8:41:03 AM
PTC Therapeutics earns $20M milestone under Evrysdi deal with Roche Seeking Alpha - 4/1/2021 8:34:57 AM
Roche, PTC Therapeutics Gets European OK of Evrysdi in Spinal Muscular Atrophy Dow Jones News - 3/30/2021 6:56:00 AM
iTeos Therapeutics shares rise 4% as Wedbush ups price target Seeking Alpha - 3/25/2021 4:19:31 PM
Ixico Shares Fall as Roche Halts Huntington's Disease Trial Dow Jones News - 3/23/2021 11:59:00 AM
Ionis Pharmaceuticals Partner Stops Dosing in Huntington's Disease Study Dow Jones News - 3/23/2021 7:15:00 AM
Roche Covid-19 Antibody Trial Meets Primary Endpoint Dow Jones News - 3/23/2021 2:50:00 AM
Genentech: Dosing to Stop in Phase III Clinical Study of Tominersen Dow Jones News - 3/22/2021 4:58:00 PM
Ionis announces discontinuation of Huntington's disease studies Seeking Alpha - 3/22/2021 4:39:33 PM
Genentech's Tecentriq meets late-stage lung cancer study main goal Seeking Alpha - 3/22/2021 6:29:16 AM
Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study Dow Jones News - 3/22/2021 2:45:00 AM
Artelo Biosciences Shares Rise 8% on Acceptance Into U.K Oncology Program Dow Jones News - 3/19/2021 10:49:00 AM
SAE   Tuesday, 12/06/11 12:22:25 PM
Re: None
Post # of 252 


Roche Acquires Verum Diagnostica GmbH as Part of Plan to Develop Comprehensive Coagulation Testing Portfolio for Diagnostic L...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed an agreement under which it will acquire 100 percent of Verum Diagnostica GmbH, based in Munich, Germany. Verum Diagnostica is a leading company in platelet function testing, the fastest-growing field in the coagulation diagnostics market.

The acquisition supports plans Roche announced in October to expand its coagulation testing product line in North America beyond physician offices and outpatient clinics with the development of a full line of coagulation analyzers for hospital and reference laboratories. The new line is expected to be introduced in the U.S. and Canada in 2014, subject to regulatory approval and other requirements.

"Improving the assessment of a patient's platelet function status is currently a significant unmet need for hematologists, cardiologists and anesthetists in order to support clinical decisions in cardiology, surgery and intensive care," said Colin Brown, Head of Roche Professional Diagnostics. "With this acquisition we gain an innovative and unique platelet function testing solution which has the potential to set new standards of patient care in this area and perfectly complements our new coagulation portfolio." Coagulation diagnostics has become an important area in clinical diagnostics and Roche has already begun to make significant investments in this field.

Under the terms of the acquisition agreement, Roche will pay Verum Diagnostica shareholders a total cash consideration of eleven million euros, and potentially a further two million euros contingent upon reaching certain performance-related milestones. The transaction is subject to customary closing conditions and is expected to close in January 2012.

Laboratory coagulation is estimated to be the fifth-largest market in professional diagnostics worldwide, representing approximately 1.3 billion USD in sales in 2010 and having a projected annual growth rate of 5.1% over the next five years. Platelet function testing represents an unmet medical need and has the potential to expand the available market significantly.

About Verum Diagnostica

Verum Diagnostica GmbH is a 100 percent subsidiary of Dynabyte Informationssysteme GmbH, developing, producing and marketing the Multiplate analyzer, test cells and reagents for the determination of platelet function in whole blood for use in hospital laboratories and near-patient settings, such as interventional cardiology, surgery and intensive care. Operating globally in more than 45 countries, the company is based in the biotech cluster and academic center of Munich, Germany, and closely cooperates with an extensive network of clinical partners. Verum Diagnostica will become part of Roche's Professional Diagnostics business area.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

All trademarks mentioned in this release are protected by law.









For further information, please contact:












Betsy Cox


Melanie Lussier




Director, Corporate Communications


Associate Manager, Communications




Roche Diagnostics Corporation


Roche Diagnostics Canada




Indianapolis, Indiana USA


Laval, Quebec, Canada




(317) 521-3911


(450) 686-3137




betsy.cox@roche.com


melanie.lussier@roche.com






SOURCE Roche Diagnostics



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences